guinea-pigs or agoutis. In practice, it has not been possible to obtain sufficient mammalian enzyme for detailed studies in animals in vivo, let alone for clinical trial.
Very soon after L-asparaginase began to be given clinically, its immunosuppressive activity was detected by the fact that the Mantoux reaction became negative. The remarkable feature of this suppression was that it only occurred while L-asparaginase was being administered. Within a day or two of stopping the administration of L-asparaginase, the patient again gave positive tests. Detailed studies in man and in animals quickly showed that both humoral and cell-mediated immune reactions were suppressed by L-asparaginase and the fact that the suppression ceases shortly after stopping treatment (i.e. by the time the L-asparaginase has been eliminated from the body) was demonstrated very clearly by skin graft rejection in experimental animals. The length of time which the skin grafts remained was determined entirely by the length of administration of the enzyme. Apart from its temporary nature, the other striking feature of immunosuppression by L-asparaginase is that it occurs without any depletion in the number of circulating lymphocytes. From a practical point of view, the toxicity encountered in continuous administration probably limits the usefulness of L-asparaginase as an immunosuppressive agent.
Almost all the studies on immunosuppressive activity have been carried out with the bacterial enzyme and the possibility therefore remains that the glutaminase activity is in some way involved in immunosuppression. While this possibility cannot be completely excluded, it is made unlikely by the fact that glutaminase-free L-asparaginase separated from agouti serum is as effective as the bacterial enzyme in suppressing in vitro the blast transformation of lymphocytes in response to: (1) plant substances such as phytohmmagglutinin; (2) exposure to soluble antigens to which the lymphocyte donor had been immunized; and (3) culturing with lymphocytes from a genetically different donor. We have collected evidence to indicate that the mechanism by which L-asparaginase causes immunosuppression in vivo is by interference with the transformation oflymphocytes into immunoblasts in response to antigenic stimulation. Investigations in several systems have shown that an essential component in the genesis of both cellmediated and humoral immunity is the transformation of stimulated cells into immunoblasts. This can be demonstrated rather clearly by collecting these immunoblasts as they leave the efferent lymphatic of a stimulated node. If these immunoblasts are removed, no systemic immunity results. We have been able to demonstrate that L-asparaginase prevents in rats the formation of immunoblasts so long as the enzyme is given at approximately the same time as the antigen. We feel that the immunosuppressive action of L-asparaginase can be fully accounted for by its interference with the transformation of lymphocytes by antigen.
L-asparaginase does not interfere with lymphocyte proliferation from lymphoid stem cells, so that the rate of recovery from lymphopenia induced by whole body exposure to X-rays is not influenced by L-asparaginase. The transformation of a small lymphocyte to an immunoblast requires a complete reorganization of the cell and the development of protein synthetic capacity for the production of antibodies. It is an attractive hypothesis that the economy of the cell during this transition period demands that the endogenous synthesis of asparagine is interrupted and that the lymphocyte relies during transformation on receiving asparagine from other sites in the body. This hypothesis explains why L-asparaginase is able to suppress immunity without there being any effect on the lymphoid organs or on the level of circulating lymphocytes. It also explains why the immunosuppressive action of Lasparaginase disappears within a day of stopping the administration of the enzyme.
[A full report of this work appears on p 189 Mathe 1971) suggested that active immunotherapy is best applied to a patient when he is carrying the smallest possible number of leukemic cells. To achieve this, we reduce the cell number by chemotherapy to in- 
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ig 1 Actuarial curves ofduration ofcomplete remissions after stopping chemotherapy in patients submitted to active immunotherapy (Immth) (Mathe et al. 1969 ) compared to controls left without any treatment. Note that time scale is geometrical duce remission and then try to get a further reduction by sequential complementary systemic chemotherapy. In addition we use intrathecal chemotherapy and CNS irradiation because of the well known isolation of some parts of the CNS from immune reactions and the high incidence of meningeal relapses in acute lymphoid leukiemia (ALL) patients.
In our first trial, started in 1964 (Mathe et al. 1969) , 30 ALL patients, aged 3-80 years, were treated in this way. They received, after induction of remission, sequential systemic cell-reducing complementary chemotherapy (one drug at a time), intrathecal chemotherapy, and CNS irradiation. They were then divided into four groups at random. The first group of 10 control patients did not receive any further treatment after cell-reducing complementary chemotherapy was stopped. The second group of 8 patients received BCG (Pasteur Institute, Paris) every fourth day and then every eighth day, through 20 5-cm cutaneous scratches arranged in a square, 2 ml of a suspension containing 75 mg/ml living bacteria being applied to the scarified area. The third group of 5 patients received each week, both intradermally and subcutaneously, 4 x 107 leukeemic cells which had been obtained from a pool of allogeneic donors suffering from ALL. These cells had been preserved at -70°C in dimethyl sulphoxide. For the first six injections the cells were treated with 4 % formol solution to inactivate any possible virus and for remaining injections they were irradiated with 4,000 rad in vitro. In the final group 7 patients were given both forms of immunotherapy.
Each of the 10 patients left without treatment after chemotherapy relapsed (Fig 1) . The average duration of the remission after chemotherapy interruption was 66 days (range 30-130 days). At the 130th day only 9 of the 20 patients given immunotherapy had relapsed and the difference between the two groups was highly significant (X 2=6l18, P<0 02). Later, 4 other patients relapsed. An examination of the relapses gives rise to the following comments: (1) the majority appeared early, which suggests that the number of tumour cells left after the cell-reducing complementary chemotherapy was greater than the maximum number that could be controlled by active immunotheradpy; (2) 4 were late in onset (one occurred in an infant in whom the BCG treatment had been stopped 44 days earlier because of a phlyctenular kerato-conjunctivitis which interrupted the treatment). Seven patients are still in remission more than three years after stopping chemotherapy, 4 for more than five years and 1 for more than six years. Fig 1 shows the differences between the groups submitted to immunotherapy and the control group. There were no significant differences between the group given BCG (5 relapses among 8 patients, treatment being stopped in 1), those given leukemic cells alone (3 relapses among 5 patients), and the group given both forms of immunotherapy (5 relapses in 7 patients). Hence it is reasonable to hope that in the strategical combination of chemotherapy and active immunotherapy better chemotherapy regimes will allow diminution of leukwemic cells to a number accessible to active immunotherapy in a greater proportion of patients.
Is it possible to increase the effect obtained from such chemoradioimmunotherapy? The first idea which came to mind was to combine the active immunotherapy with cytostatic chemo- another trial: these two forms ofchemotherapy, because they are immunosuppressive, lessen the effect of immunotherapy (patients infirstperceptiblephase of the disease, al ages). Note that time scale is geometrical therapy or with antiviral treatment (to try and avoid possible 'viral reinduction' of the disease). This was attempted in a trial in which the patients were randomized, after pre-immunotherapy complementary cell-reducing treatment, into three groups: (1) submitted to immunotherapy alone: that is, BCG, Corynebacterium parvum (another systemic adjuvant) (see Mathe 1971) and leukimic cells; (2) submitted to the same immunotherapy combined with cytostatic chemotherapy (vincristine); (3) submitted to the same immunotherapy combined with antiviral chemotherapy (adamantadine). Preliminary results show a good effect of immunotherapy alone but deterioration with chemotherapy or antiviral treatment (Fig 2) , explicable by an immunosuppressive effect, known for vincristine (Amiel et al. 1967 ) and recently demonstrated for adamantadine (Bredt & Mardiney 1969) .
These results indirectly confirm the effectiveness of active immunotherapy and show that it should be administered alone. They also suggest that such treatment is more effective if given early: Fig 3 shows that as far as duration of complete remission is concerned, much better results are obtained when patients are given active immunotherapy at the very beginning of their disease than when it is applied for a relapse or after a period of conventional treatment. The Fig 2. A, patients submitted to active immunotherapy atfirstperceptible phase ofdisease, at the very beginning. B, patients submitted to active immunotherapyfor a relapse, or previously treated with conventional treatment further development of active immunotherapy will depend on the outcome of at least two research programmes: the preparation of a more efficient specific vaccine and the preparation of more efficient and more satisfactory systemic adjuvants for nonspecific stimulation. It has not yet been demonstrated in animals that any pure soluble preparation of tumourassociated antigen is better than tumour cells for specific immunization, and Fairley (1970) has shown that vaccination of acute leukemia patients with leukwemic cells increases transformation of their lymphocytes by their own leukwmic cells. The present problem, therefore, is essentially to make more cells available and if possible to render them more antigenic. These objectives may be achieved by use of bulk cultures producing unlimited quantities of cells; Belpomme et al. (1969) obtained results in our laboratory which suggest that tumour-associated immunogenicity of cultured leukemia cells is increased compared with that of fresh cells.
As far as non-specific stimulation of immune reactions is concerned, efforts are being made in several centres to discover and prepare new adjuvants: we have developed a screening system (Mathe 1972) which has already revealed the immunostimulatory effect of several microorganisms and substances, two of which are at the stage of clinical trial. At first we had only BCG, which is effective only when given by scarification. Bluming (1972, personal communication) , employing a battery of immunological tests, confirmed the efficiency of Pasteur Institute BCG applied by scarification with our technique. He was able to potentiate both some delayed cutaneous sensitivity responses and to a lesser degree the specific circulating immunoglobulin level. Neither effect has thus far been noted by him with Glaxo BCG injected intradermally. However, two other systemic adjuvants are now being studied in patients: C. parvum, which we used in the second trial mentioned earlier, and poly IC, which we showed was able to induce remissions in patients with perceptible disease but having only a few leukemic cells in their bone marrow (Mathe et al. 1970) (Table 1) .
Such is the strategy we are applying in the treatment of ALL, the most exciting result being the appearance of a plateau in the actuarial cumulative duration of the first remission for a fairly high percentage of patients. We know from Burchenal's study (1970) that the exceptional long-term survivors after conventional treatment may still relapse after 5 years; although we have had no relapse in our first trial between 960 and 1,970 days (up to April 1 1971) after stopping chemotherapy, it is still too early to know if immunotherapy will avoid such very late relapses and at present the plateau phenomenon can only be interpreted as a 'cure expectancy' expression.
The comparison of the results of our first treatment trial (Mathe et al. 1969 ) and those of the patients only submitted to immunotherapy in the second published trial does not show any important difference. We wondered if there may not be several varieties of ALL, some sensitive to immunotherapy and others insensitive, which would limit the possibilities of progress. We therefore subclassified our ALL cases in a double blind retrospective study into four varieties on the basis of the morphology of the leukwmic cells in the first bone marrow smear . We distinguished the cells according to degree of differentiation, calling 'prolymphoblastic' AL (PLbAL) the less differentiated variety, 'prolymphocytic' AL (PLcAL) the most differentiated, and 'lymphoblastic' the intermediate varieties which we divided into two classes, the 'macrolymphoblastic' AL (MLbAL) with cell diameter more than 12 pm (mode 13), and the 'microlymphoblastic' AL (mLbAL) with cell diameter less than 12 pm (mode 11) (Fig 4) . Table 2 shows patients' age and sex for the different subvarieties, the most noticeable feature being the great predominance of the microlymphoblastic type in children.
The most important feature of this apparently sophisticated but technically simple classification resides in the correlation between this typing and prognosis, possibly curability. Fig 5 shows the actuarial curves of the duration of the first remission, and the curves of survival diagnosis for all patients. Fig 6 shows the curves for the patients less than 20 years old. One can see important differences between the types of ALL: only the microlymphoblastic (mLbAL) and the prolymphocytic (PLcAL) types in the first remission present duration actuarial curves which, after an initial fall, form a plateau for 50% or more of the patients. So far as the survival actuarial curves for all ages are concerned, a plateau was obtained for three varieties (the former two and the macrolymphoblastic type). The dissociation of the first remission and survival curves for the MLbAL variety suggests that it is as sensitive to chemotherapy as mLbAL and PLcAL but, unlike them, is resistant to active immunotherapy. This is an indication to administer a longer complementary chemotherapy in this variety. The prognosis of mLbAL is particularly good, for about 90% of patients under 20 belong to the survival curve plateau. We are currently comparing this Giemsa typing with information from cytochemistry, electron microscopy, immunological investigation and cell kinetics. 
